<?xml version="1.0" encoding="UTF-8"?>
<ref id="rmv2143-bib-0104">
 <label>104</label>
 <mixed-citation publication-type="journal" id="rmv2143-cit-0104">
  <string-name>
   <surname>Hoffmann</surname>
   <given-names>M</given-names>
  </string-name>, 
  <string-name>
   <surname>Schroeder</surname>
   <given-names>S</given-names>
  </string-name>, 
  <string-name>
   <surname>Kleine‐Weber</surname>
   <given-names>H</given-names>
  </string-name>, 
  <string-name>
   <surname>Müller</surname>
   <given-names>MA</given-names>
  </string-name>, 
  <string-name>
   <surname>Drosten</surname>
   <given-names>C</given-names>
  </string-name>, 
  <string-name>
   <surname>Pöhlmann</surname>
   <given-names>S</given-names>
  </string-name>. 
  <article-title>Nafamostat mesylate blocks activation of SARS‐CoV‐2: new treatment option for COVID‐19</article-title>. 
  <source xml:lang="en">Antimicrob Agents Chemother</source>. 
  <year>2020</year>;
  <volume>64</volume>:
  <fpage>754</fpage>–
  <lpage>820</lpage>. 
 </mixed-citation>
</ref>
